Cases
Cases
Updated Oct 20, 5:17 AM ET
Sangamo Therapeutics is pursuing a court-approved asset sale to PTC Therapeutics for $111 million in closing consideration, plus contingent milestone payments and assumed liabilities, under the September 2 sale order Dkt. 426. The court authorized additional contract transfers effective as of closing in its October 2 assignment order Dkt. 494, and a December 15, 2026 omnibus hearing is scheduled under the October 16 order Dkt. 516.
Motion1:00 PM ETDkt. 471Motion of Debtor for Entry of an Order Extending Period Within Which the Debtor May Remove Actions Pursuant to 28 U.S.C. § 1452 and Rule 9027 of the Federal Rules of Bankruptcy Procedure and Granting Related Relief [Hearing scheduled for 11/2/2026 at 01:00 PM at US Bankruptcy Court, 824 Market St., 3rd Fl., Courtroom #7, Wilmington, Delaware. Objections due by 10/5/2026.] (Filed by Sangamo Therapeutics, Inc.)
in 12 daysSearch available documents for this case. Full docket access requires Pro.
Open case researchDebt-Free Sangamo Therapeutics Files Chapter 11 With $75M Sale Bids ·
Case facts and filing dates come from court records.
Updated Oct 20, 5:17 AM ET
Sangamo Therapeutics is pursuing a court-approved asset sale to PTC Therapeutics for $111 million in closing consideration, plus contingent milestone payments and assumed liabilities, under the September 2 sale order Dkt. 426. The court authorized additional contract transfers effective as of closing in its October 2 assignment order Dkt. 494, and a December 15, 2026 omnibus hearing is scheduled under the October 16 order Dkt. 516.
Motion1:00 PM ETDkt. 471Motion of Debtor for Entry of an Order Extending Period Within Which the Debtor May Remove Actions Pursuant to 28 U.S.C. § 1452 and Rule 9027 of the Federal Rules of Bankruptcy Procedure and Granting Related Relief [Hearing scheduled for 11/2/2026 at 01:00 PM at US Bankruptcy Court, 824 Market St., 3rd Fl., Courtroom #7, Wilmington, Delaware. Objections due by 10/5/2026.] (Filed by Sangamo Therapeutics, Inc.)
in 12 daysSearch available documents for this case. Full docket access requires Pro.
Open case researchDebt-Free Sangamo Therapeutics Files Chapter 11 With $75M Sale Bids ·
Case facts and filing dates come from court records.